Holen Sie sich die Stockscreener-App
7.07
3.94%
-0.29
Handel nachbörslich:
7.05
-0.02
-0.28%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Solid Biosciences grants 77,500 options to director | SLDB Insider Trading - Stock Titan
Director at Solid Biosciences (NASDAQ: SLDB) granted 77,500 options - Stock Titan
Solid Biosciences (SLDB) director awarded 77,500 stock options at $6.61 strike - Stock Titan
Solid Biosciences (SLDB) director awarded 77,500 options via Perceptive Advisors - Stock Titan
Director at Solid Biosciences (SLDB) granted 77,500 stock options at $6.61 - Stock Titan
Solid Biosciences (SLDB) director receives 77,500 stock options at $6.61 exercise price - Stock Titan
Director at Solid Biosciences (NASDAQ: SLDB) receives 77,500 stock options grant - Stock Titan
Solid Biosciences (SLDB) grants director 77,500 stock options at $6.61 - Stock Titan
Solid Biosciences director granted 77,500 options | SLDB Insider Trading - Stock Titan
Solid Biosciences Shareholders Approve Directors and Share Increase - TipRanks
Solid Biosciences (NASDAQ: SLDB) shareholders approve doubling authorized stock - Stock Titan
Should I Buy SLDB (Solid Biosciences Inc.) | AI Analysis, Technical & News Insights - Kavout
SLDB: Gene therapy programs show robust efficacy, safety, and regulatory momentum for key indications - TradingView
Solid Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB) - The Globe and Mail
SLDB (NASDAQ: SLDB) supplement lists updated selling stockholders and holdings - Stock Titan
Solid Biosciences Rises as Investors Focus on Rare-Disease Pipeline - Bez Kabli
H.C. Wainwright raises Solid Biosciences price target on FA trial progress - Investing.com UK
SLDB Maintained by HC Wainwright & Co. -- Price Target Raised to $25 - GuruFocus
SLDB: Duchenne and FA gene therapy programs show strong progress, with pivotal FDA meetings ahead - TradingView
H.C. Wainwright raises Solid Biosciences price target on FA trial progress By Investing.com - Investing.com South Africa
Solid Biosciences And Nanomosaic Announce Co-Marketing Agreement To Advance Gene Therapy Delivery And Analytics - TradingView
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics - PR Newswire
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences joins Jefferies Global Healthcare Conference with CEO Bo Cumbo fireside chat - Traders Union
Watch Solid Biosciences CEO at two June healthcare investor events - Stock Titan
Solid Biosciences to Participate at Upcoming Investor Conferences - The Manila Times
Solid Biosciences (SLDB) Edges Higher, Testing Key Resistance After Recent GainsIchimoku Cloud - The Legal Advocate
Solid Biosciences Inc. spotlights Patrick González SGT-003 insights at major DMD conference - Traders Union
Solid Biosciences begins phase 3 trial for Duchenne therapy By Investing.com - Investing.com Nigeria
Solid Biosciences (SLDB) Surges 3.93% as Bullish Momentum BuildsCall Resistance - The Legal Advocate
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
Solid Biosciences Inc. (SLDB) Q1 2026 Earnings: Wider Loss Reported as Pipeline Investment ContinuesUpward Estimate Revision - thelegaladvocate.com
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
SLDB Q1 2026 Earnings: Wider-than-Expected Loss as Solid Biosciences Advances Gene Therapy PipelineEstimate Revision Count - newsline.com
SLDB Stock Price, Quote & Chart | SOLID BIOSCIENCES INC (NASDAQ:SLDB) - ChartMill
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months? - Insider Monkey
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals - ChartMill
SLDB Reiterated by Wedbush -- Price Target Maintained at $16.00 - GuruFocus
Solid Biosciences Price Target Maintained With a $16.00/Share by Wedbush - Moomoo
StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate - Genetic Engineering and Biotechnology News
SLDB: Citigroup Lowers Price Target but Maintains Buy Rating | S - GuruFocus
H.C. Wainwright Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Citigroup Maintains Solid Biosciences (SLDB) Buy Recommendation - MSN
Should You Sell Solid Biosciences (SLDB) After -10.09% Drop? 2026-05-15Double Bottom - newsline.com
Solid Biosciences stock (US8317541063): Piper Sandler raises price target to $18 - AD HOC NEWS
Solid Biosciences Inc. to host webinar on SGT-003 gene therapy for Duchenne - Traders Union
Number of shareholders of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Wedbush Adjusts Price Target on Solid Biosciences to $16 From $17, Maintains Outperform Rating - Moomoo
SLDB Maintained by Piper Sandler -- Price Target Raised to $18 - GuruFocus
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):